Sebastian Gensior

The promise of cellular reprogramming through Yamanaka factors represents one of the most profound scientific contradictions in modern medicine: a Nobel Prize-winning technology with 109% lifespan extension in aged mice and $6+ billion in investment, yet plagued by <1% efficiency rates, severe cancer risks, and zero approved human

Weekly Term Sheet: Pharma & Biotech Deals (August 25–28, 2025) Key Deal Highlights Deal Type Companies Value Key Asset/Focus Acquisition AbbVie acquires Gilgamesh Up to $1.2B Bretisilocin (psychedelic therapy) Royalty Purchase Royalty Pharma buys BeOne's Imdelltra royalty $950M Amgen's lung cancer BiTE R&

Introduction: A Wave of Biosimilar Challenges and the "Patent Cliff" The biopharmaceutical industry is witnessing a surge of patent infringement battles over biosimilars in 2025. A major reason is the "patent cliff" -- a wave of blockbuster biologic drugs losing patent protection around this time. As patents

Investor Syndicate and Stakeholders in the $300 Million Round The new biotech (not yet officially named) is backed by a $300 million financing commitment led by Bain Capital, with other key stakeholders and co-investors involved. Beyond Bain's Life Sciences and Private Equity funds, the Canada Pension Plan

Origin Story: From Niche Pioneer to Public Trust DRI Healthcare's roots go back to 1989, when it began as one of the first investment groups dedicated to pharmaceutical royalty monetization. Originally known as Drug Royalty Corporation, the firm spent the 1990s and 2000s quietly building expertise in buying

The biotech investment ecosystem in late August 2025 presents a complex landscape of cautious recovery, selective capital deployment, and strategic adaptation to persistent market challenges. With nearly 40% of biotechs operating with less than 12 months of cash runway and the XBI index showing mixed performance, the sector is navigating

The psychedelics industry entered August 2025 with approximately $1.2 billion in combined cash reserves across six major public companies, yet quarterly burn rates exceeding $150 million threaten the sector's viability within 24 months. Following the FDA's rejection of MDMA-assisted therapy in August 2024, which

The great wheel of computing infrastructure turns full circle: from centralized mainframes to distributed systems to cloud centralization and now back to intelligent decentralization. When a16z Abandons Its Own Cloud Gospel In the era of foundation models, multimodal AI, LLMs, and ever-larger datasets, access to raw compute is still

Biopharma dealmaking slows amid regulatory storm The week of August 18-23, 2025 marked an unusually subdued period for biopharma transactions, with only 14 deals announced compared to typical weekly averages exceeding 25-30 transactions. The total disclosed deal value reached approximately $5.5 billion, though most arrangements featured milestone-

The pharmaceutical industry's adoption of Palantir Technologies reveals a fundamental tension in enterprise software architecture that goes beyond simple market positioning. At its core, this is a story about whether a platform designed for counterterrorism and battlefield intelligence can meaningfully transform drug discovery and clinical trials, or whether